news
Novavax’s COVID-19 vaccine highly effective in preventing disease
New Phase III trial data suggests Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is 90 percent effective at preventing COVID-19 illness.
List view / Grid view
NVX-CoV2373
news
Novavax’ COVID-19 vaccine almost 90 percent effective in Phase III trials
In UK trials where 60 percent of COVID-19 cases were caused by the Alpha SARS-CoV-2 variant, the NVX-CoV2373 COVID-19 vaccine was 89.7 percent effective.
news
NVX-CoV2373 vaccine 90 percent effective in preventing symptomatic COVID-19
US trial results show NVX-CoV2373 was safe and effective in preventing symptomatic COVID-19, including in high-risk populations.
news
Co-administration of flu and COVID-19 vaccines safe and effective
A trial comparing co-administration of influenza and COVID-19 vaccines to COVID-19 vaccine dosing alone found little effect on vaccine efficacy.
news
Paediatric and adolescent COVID-19 vaccines update
The EMA is evaluating whether to lower the age at which Comirnaty can be administered and Novavax has begun testing its COVID-19 vaccine in paediatric patients.
news
Novavax’ COVID-19 vaccine to be included in UK’s mixed regimen study
Novavax has agreed to participate in the University of Oxford’s Com-COV2 study evaluating the safety and efficacy of regimens consisting of doses of COVID-19 vaccines from different manufacturers.
news
GSK to provide fill and finish capacity for Novavax’ COVID-19 vaccine
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
news
EMA begins rolling review of Novavax’s NVX-CoV2373 COVID-19 vaccine
The review will evaluate data from preclinical and clinical studies of NVX-CoV2373 to expedite the vaccine’s marketing authorisation approval later.
news
COVID-19 vaccine shows promise against UK’s new variant
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and 85.6 percent effective against the B.1.1.7 SARS-CoV-2 variant, in a Phase III trial.
news
Baxter BioPharma Solutions to manufacture Novavax’s COVID-19 vaccine
The agreement is expected to advance the commercial-scale manufacturing of the NVX-CoV2373 to enable it to be distributed across Europe following regulatory approval.
news
FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidate
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
news
Novavax begins Phase III COVID-19 vaccine efficacy trial
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
news
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
news
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
news
First patients enrolled in Phase II trial of Novavax COVID-19 vaccine
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
